Join to View Full Profile
1740 W Taylor StChicago, IL 60612
Phone+1 866-600-2273
Fax+1 312-569-8114
Dr. Molokie is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Loyola University Medical CenterFellowship, Hematology and Medical Oncology, 1987 - 1989
Cook County Health and Hospitals SystemInternship, Internal Medicine, 1983 - 1984
University of Illinois College of MedicineClass of 1983
Certifications & Licensure
IL State Medical License 1985 - 2026
American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
Clinical Trials
- Study of Decitabine and Tetrahydrouridine (THU) in Patients With Sickle Cell Disease Start of enrollment: 2012 Aug 01
- A Phase II Trial of Regadenoson in Sickle Cell Anemia Start of enrollment: 2013 Jul 01
- A Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease Start of enrollment: 2020 Jan 24
Publications & Presentations
PubMed
- Mitochondrial Retention and Autophagy Dysregulation Drive Oxidative Stress in Sickle Cell Disease Erythrocytes.Jagadeesh Ramasamy, Prasanth Kumar Punathil Kannan, Sugasini Dhavamani, Savitha Palanimuthu, Robert Molokie
Experimental Hematology. 2025-10-02 - 1 citationsDiabetes mellitus and APOL1 genotype increase the risk for chronic kidney disease progression in sickle cell disease.Ryan Sun, Anand Srivastava, Joseph L Zapater, Franklin Njoku, Jin Han
Blood. 2025-06-12 - Association of COMT rs4680 Genotype With Chronic Neuropathic Pain Experience in Patients With Sickle Cell Disease.Abigail R Islam, Gebre-Egziabher Kiros, Rachael O Ajiboye, Keesha Powell-Roach, Miriam O Ezenwa
Pain Management Nursing. 2025-06-01
Abstracts/Posters
- Impact of Intravenous Opioid Shortage on Managing Pain Crisis in Sickle Cell DiseaseRobert E. Molokie, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Risk Factors for Kidney Disease in Hb SC and Hb S_+-Thalassemia Sickle Cell DiseaseRobert E. Molokie, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Press Mentions
$7.1M Grant to Review Opioid Alternatives to Treating Sickle Cell Disease PainOctober 5th, 2020
Genetic Variant Might Be a Better Marker for Heart DiseaseApril 11th, 2018
NIH Awards $4.6 Million for Chronic Pain ResearchFebruary 26th, 2018- Join now to see all
Grant Support
- Exploring the Mediterranean Diet as A Promising Approach for Alleviating Chronic Pain in Sickle Cell DiseaseUNIVERSITY OF ILLINOIS AT CHICAGO2025–2027
- Hybrid Effectiveness-Implementation Trial of Guided Relaxation and Acupuncture for Chronic Sickle Cell Disease PainUNIVERSITY OF ILLINOIS AT CHICAGO2020–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
